All relevant data are within the paper and its Supporting Information file.

Introduction {#sec001}
============

Clusterin, coded by a highly conserved gene, was first identified in ram's rete testis fluid\[[@pone.0161150.ref001]\]. Now, clusterin is widely found in various tissues and organs and is involved in a number of biological processes, including fluid transport, cell apoptosis, cell adhesion, etc\[[@pone.0161150.ref002]--[@pone.0161150.ref005]\]. The abnormal expression of clusterin protein is reportedly associated with Alzheimer's disease, aging, cardiovascular diseases, inflammatory diseases, and tumourigenesis\[[@pone.0161150.ref006]--[@pone.0161150.ref010]\]. Clusterin protein has several isoforms arising from alternative protein splicing. Two isoforms of clusterin with opposing actions on cell apoptosis have been identified; one is secretory clusterin (sCLU), which prevents cell apoptosis, and the other is nuclear clusterin (nCLU), which induces cell apoptosis\[[@pone.0161150.ref004]\]. sCLU, the main isoform, has been extensively researched in the field of tumour diagnosis and prognosis considering its antiapoptotic function.

In most clinical studies, sCLU has been revealed to be a poor prognosis indicator associated with tumour relapse and metastases, including bladder cancer, prostate cancer, and lung cancer\[[@pone.0161150.ref011]--[@pone.0161150.ref018]\]. For instance, Matsuwaki et al. found that higher sCLU expression in the lymph-node tumour of nonsmall-cell lung cancer (NSCLC) patients predicted a higher recurrence-free survival (RFS), which suggests that sCLU is associated with enhanced NSCLC cell survival and proliferation and thus leads to poor prognosis\[[@pone.0161150.ref017]\]. However, some studies have presented contradictory or insignificant results, even in the same kind of malignancy. Albert et al. and Panico et al. studied NSCLC patients and found that higher sCLU expression in the original tissue specimen is associated with lower RFS. Li et al. found no significant relationship between sCLU expression and RFS\[[@pone.0161150.ref019]--[@pone.0161150.ref021]\]. In addition, the relationship between sCLU and overall survival (OS) has also been widely researched in various tumour studies\[[@pone.0161150.ref019]--[@pone.0161150.ref036]\], whose results also present contradictory results about the prognostic function of sCLU.

The role of CLU is controversial and has been previously stated and described in many reviews. Many studies have elucidated the antiapoptotic function of the sCLU and the positive association between sCLU and epithelial--mesenchymal transition (EMT), which suggest that sCLU protein can be a promoter of tumour-cell survival\[[@pone.0161150.ref037]\]. However, according to existing clinical data, whether sCLU acts as a good or bad indicator in clinical tumour progression is unclear. Thus, we conducted this meta-analysis to identify the specific clinical prognostic role of sCLU protein using pooled survival data. In addition, given that the method for detecting sCLU expression differs in each study especially in immunohistochemistry (IHC), we discussed the pooled data in different groups using various scoring methods and then valued the heterogeneity in each group. This technique may partly reflect the quality of a series of IHC studies using the same scoring method considering the subjectivity of IHC studies. If high heterogeneity exists or the IHC scoring results significantly differed from one another in a series of studies using the same scoring method, the group of studies can be considered hardly reproducible and subjective after excluding other factors (pathology type, an individual heterogeneous study, etc.). Subsequently, an incorrect clinical consequence ensued. The heterogeneity in each group was discussed in this meta-analysis. This is the first meta-analysis to evaluate the relationship between sCLU IHC expression and the prognosis of patients with various cancers.

Materials and Methods {#sec002}
=====================

Search strategy {#sec003}
---------------

This study aimed to clarify the comprehensive predictive value of sCLU or cytoplasmic clusterin in human malignant neoplasms. Online databases including PubMed, EMBASE and Web of Science were searched to identify relevant literature published until 3 April 2016. The searched keywords were "clusterin protein and (cancer or carcinoma or tumour or neoplasm) and (survival or prognosis or relapse or recurrence)." The title and abstract of the citations were inspected to identify the articles appearing to report the study of sCLU's relationship with survival or recurrence. After a preliminary evaluation of the published papers, we found the clusterin expression was measured in various ways, including by IHC, enzyme-linked immunosorbent assay (ELISA), real-time polymerase chain reaction (qPCR), and northern blot, among which IHC is the most common method for clusterin-expression detection in the field of prognosis analyses. In this meta-analysis, we focused on papers in which IHC method was utilised for clusterin detection because of the extremely limited amount of papers in which other methods were applied. ELISA, Northern blot, and qPCR were applied in only three, three, and one paper, respectively ([Fig 1](#pone.0161150.g001){ref-type="fig"}). In addition, we searched literature published in Chinese to better understand the predictive role of sCLU. One study published in Chinese was finally included\[[@pone.0161150.ref022]\].

![Flow diagram of the study selection process.](pone.0161150.g001){#pone.0161150.g001}

Quality assessment {#sec004}
------------------

This meta-analysis was strictly performed according to the preferred reporting items of the systematic reviews and meta-analysis (PRISMA) statement. Our inclusion criteria was derived from the published guidelines (REMARK) for reporting IHC-based tumour marker studies, which was from a previously described protocol\[[@pone.0161150.ref038]\]. The criteria has been applied to the quality assessment of IHC-based meta-analysis in several studies before\[[@pone.0161150.ref039], [@pone.0161150.ref040]\]. The inclusion criteria were as follows: (1) a well-defined population and study design, i.e., all patients included in the study suffered a definite carcinoma and received the same therapeutic schedule, such as the same chemotherapy regimen; (2) a clear description of the IHC method, including the tissue specimens' preparation and storage, the details of the primary antibody (specific to sCLU) and secondary antibody used, and the positive or negative control or the pictures of the staining; (3) a clear description of the scoring method of the IHC and an explicit cutoff point that differs between the positive- and negative-expression group; (4) a precise definition of the clinical endpoints examined and reporting of the resulting hazard ratio (HRs) or risk ratio values, including 95% confidence intervals (CIs) or survival curve; and (5) no overlapping with other datasets in the present study. Studies were deemed eligible according to the aforementioned criteria to maintain the quality of the meta-analysis. Given that the clusterin IHC scoring method varied among different studies, we divided the included papers in this meta-analysis into three groups according to the scoring and reporting protocols: group 1 was scored by both intensity staining and proportion of the staining cells, group 2 was scored by the staining intensity, and group 3 was scored by the proportion of staining cells.

We separately discussed the pooled data, and a sensitivity analysis for each group was conducted to prevent a highly heterogeneous study ([Fig 2](#pone.0161150.g002){ref-type="fig"}). In addition, we analysed the heterogeneity of each group individually by comparing their *I*^*2*^ values.

![Sensitivity of each included study in three different groups.\
(A) Sensitivity analysis of OS in group 1. (B) Sensitivity analysis of RFS in group 1. (C) Sensitivity analysis of OS in group 2. (D) Sensitivity analysis of RFS in group3.](pone.0161150.g002){#pone.0161150.g002}

Data extraction {#sec005}
---------------

Data were extracted from the different groups, and the extracted-data elements included the following: (1) first author's name and publication year; (2) study population, ethnicity, nationality, disease type, and main type of pathology; (3) median or mean age of patients; (4) IHC scoring methods, cutoff definition, and follow-up time; and (5) HRs associated with upregulated clusterin expression for OS, RFS, and disease-free survival (DFS) along with their 95% CIs. In some papers that provided only Kaplan--Meier curves, the HRs and their 95% CIs were calculated using graphical survival plots as previously described\[[@pone.0161150.ref041], [@pone.0161150.ref042]\]. All these data are listed in [Table 1](#pone.0161150.t001){ref-type="table"}.

10.1371/journal.pone.0161150.t001

###### Main characteristics of studies included and HRs for patient OS or DFS/RFS in association with clusterin expression.

![](pone.0161150.t001){#pone.0161150.t001g}

                            Case number   OS                          DFS/RFS                                                                        
  -------- ---------------- ------------- ----- --------------------- --------- -------------------- ------ ---------- ------------------- --------- -----------
  group1   Luo, 2005        32            37    2.49(0.82 to 7.55)    0.01                                  SC         Bladder Cancer      TCC       Asian
           Yang,2009        40            46    1.38(0.61 to 3.13)    0.03                                  SC         Ovarian Cancer      AdenoCA   Asian
           MIYAKE,2006      59            113   1.68(0.8 to 3.52)     0.17                                  SC         PCA                 AdenoCA   Asian
           Zhang,2006       96            62    1.21(0.17 to 8.47)    0.00                                  SC         Breast Cancer       AdenoCA   Asian
           Watari,2008      21            31    1.85(0.27 to 12.94)   0.01                                  SC         Cervical Cancer     SqCa      Asian
           BI, 2010         47            118   1.01(0.6 to 1.71)     0.96                                  Reported   Gastric Cancer      AdenoCA   Asian
           He,2009          47            63    1.1(0.62 to 1.97)     0.15      1.27(0.75 to 2.15)   0.09   SC         Esophageal Cancer   SqCa      Asian
           Panico,2013      34            49    0.41(0.17 to 1.01)    0.05      0.46(0.21 to 1.00)   0.05   Reported   NSCLC               AdenoCA   Caucasian
           MIYAKE,2005      33            43                                    1.67(0.26 to 2.63)   0.02   Reported   PCA                 AdenoCA   Asian
           Kurahashi,2005   61            70                                    1.65(0.68 to 4.01)   0.00   SC         Renal Cancer        RCC       Asian
           YOM,2009         97            89                                    1.39(0.35 to 5.59)   0.04   SC         Breast Cancer       AdenoCA   Asian
           Harada,2012      43            79                                    2.51(1.21 to 5.22)   0.00   SC         RCC                 AdenoCA   Asian
           Matsuwaki,2014   24            40                                    1.55(0.74 to 2.58)   0.04   Reported   NSCLC               SqCa      Asian
  group2   Albert,2007      44            62    0.487(0.27 to 0.89)   0.01      0.354(0.12 to 1.2)   0.02   Reported   NSCLC               SqCa      Caucasian
           Partheen, 2008   NM            NM    0.29(0.08 to 1.08)    0.00                                  SC         Ovarian Cancer      AdenoCA   Caucasian
           Kevans,2009      136           115   2.88(1.48 to 5.61)    0.00                                  SC         Colorectal Cancer   AdenoCA   Caucasian
           Watari,2010      14            32    2.79(0.4 to 19.19)    0.01                                  SC         Cervical Cancer     SqCa      Asian
           Hassan,2011      15            32    2.22(0.12 to 42.52)   0.04                                  SC         Ovarian Cancer      AdenoCA   Asian
           Jin,2012         17            35    0.65(0.283 to 1.49)   0.31                                  Reported   Pancreatic Cancer   AdenoCA   Asian
           Watari,2012      8             26    3.32(0.95 to 11.69)   0.02                                  SC         Cervical Cancer     SqCa      Asian
           Tobisawa,2013    92            13    4.1(1.27 to 13.27)    0.02                                  Reported   T-cell lymphoma     MF        Asian
  group3   Xie,2001         16            17    0.37(0.11 to 1.32)    0.01                                  SC         Pancreatic Cancer   AdenoCA   Asian
           KRÜGER,2006      29            89                                    2.69(0.97 to 7.51)   0.05   Reported   Bladder Cancer      TCC       Caucasian
           KRÜGER,2006      36            105                                   2.19(1.05 to 4.57)   0.06   SC         Breast Cancer       AdenoCA   Caucasian
           Redondo,2009     31            72                                    2.01(1.03 to 3.9)    0.04   Reported   Colorectal Cancer   AdenoCA   Caucasian
           Li,2010          70            51    1.63(0.22 to 12.03)   0.37      0.92(0.41 to 2.09)   0.62   SC         NSCLC               AdenoCA   Asian

AdenoCA, adenocarcinoma; DFS, disease-free survival; HR (high vs low); NM, not mentioned; NSCLC, non-small cell lung cancer; OS, overall survival; PCA, prostate carcinoma; RCC, renal cell carcinoma; RFS, relapse-free survival; SC, survival curve; SqCa, squamous carcinoma.

Statistical analysis {#sec006}
--------------------

Fixed-effect summary HRs and 95% CIs were calculated using the Mantel--Haenszel method and the random-effect model based on the DerSimonian--Laird method according to heterogeneity among the pooled studies\[[@pone.0161150.ref043]\]. Heterogeneity was assessed using Higgins I^2^ statistic and Cochran Q test\[[@pone.0161150.ref044]\]. A random-effect model was applied if significant heterogeneity was observed (p\<0.10 or *I*^*2*^ \>50%); otherwise, the fixed-effect model was utilised. An HR value greater than 1 indicated poor outcome for the upregulated to the downregulated clusterin expression and was considered statistically significant if the 95% CI did not include 1, with P \< 0.05. Egger's linear regression test was applied to estimate the publication bias with a funnel plot\[[@pone.0161150.ref045]\]. A p value less than 0.05 was considered statistically significant. The meta-analyses were carried out with Stata12 (StataCorp LP, College Station, TX, USA).

Result {#sec007}
======

Summary of the enrolled studies {#sec008}
-------------------------------

Our search of clusterin prognostic literature yielded 454 manuscripts ([S1 File](#pone.0161150.s001){ref-type="supplementary-material"}) using PubMed, EMbase, and Web of Science. Sixty articles were identified through primary title and abstract evaluation, and studies were excluded if they were review articles, did not use a human subject, or were not related to the current meta-analysis. After a primary evaluation, full text articles were obtained for these 60 manuscripts; 11 studies were excluded secondarily because they did not provide the survival data (HRs and survival curves), 12 studies were excluded because they were not directly related to the specific outcome, and 13 articles were excluded because they did not use the IHC method for sCLU detection. Ultimately, all remaining articles were checked secondarily, and no overlapping datasets were found ([Fig 1](#pone.0161150.g001){ref-type="fig"}). A total of 26 articles were included in our meta-analysis finally.

The main features of the 26 enrolled articles are systematically summarised in [Table 1](#pone.0161150.t001){ref-type="table"}. Eight studies focused on RFS, fourteen reported patient OS, and four investigated OS and DFS. Among these studies, a total of 2631 participants were included; 19 studies focused on Asians, and 7 evaluated Caucasians. The malignant neoplasms assessed in these studies included bladder cancer, ovarian cancer, prostate cancer, breast cancer, cervical cancer, gastric cancer, esophageal cancer, colorectal cancer, lymphoma, and NSCLC. Sixteen articles focused on the pathological type of adenocarcinoma (adenoCA), six assessed squamous carcinoma (SqCa), two evaluated transitional cell carcinoma (TCC), one focused on lymphoma and one detected renal cell carcinoma(RCC). Three groups were divided as previously described in this analysis according to the IHC scoring method. In total group 1 had 13 studies, group 2 had 8 studies, and group 3 had 5 studies.

Sensitivity analyses {#sec009}
--------------------

Our sensitivity analyses in the three different groups (both in OS and DFS/RFS analyses) did not indicate alterations in the results if any individual study was excluded ([Fig 2](#pone.0161150.g002){ref-type="fig"}), suggesting that no single study significantly influenced the pooled HR or the 95% CI.

Recurrence associated with sCLU expression {#sec010}
------------------------------------------

A total of 11 studies were included in the DFS/RFS analysis. Both groups 1 and 3 revealed a risk factor of increased sCLU expression (group 1: pooled HR = 1.35, 95% CI = 1.01 to 1.79; group 3: pooled HR = 1.80, 95% CI = 1.22 to 2.65), as determined by a fixed-effect model (group 1: p = 0.100, *I*^*2*^ = 43.6%; Group 3: p = 0.311, *I*^*2*^ = 16.2%) ([Fig 3](#pone.0161150.g003){ref-type="fig"}) in a combined analysis. Group 2 involved only one study (HR = 0.354, 95% CI = 0.12 to 1.2).

![Forest plots of merged analyses of disease-free survival (DFS)/relapse-free survival (RFS) in association with sCLU expression in different groups.\
Forest plots of merged analyses of overall survival (OS). Squares and horizontal lines represent study-specific HRs and 95% CIs, respectively. The areas of the squares correspond to weights, and the diamonds represent overall HRs and 95% CIs. (A) Forest plots of merged analyses of RFS/DFS in group 1. (B) Forest plots of merged analyses of RFS/DFS in group3.](pone.0161150.g003){#pone.0161150.g003}

OS associated with sCLU expression {#sec011}
----------------------------------

A total of 19 studies were included in the OS analysis. In all groups, no significant relationship existed between sCLU and OS (group 1: pooled HR = 1.13, 95% CI = 0.86 to 1.50; group 2: pooled HR = 1.14, 95% CI = 0.82 to 1.60; group 3: pooled HR = 1.64, 95% CI = 0.95 to 2.83), as determined by a fixed-effect model in groups1 and 3 (p = 0.276, *I*^*2*^ = 19.4%; group 3: p = 0.217, *I*^*2*^ = 34.3%) and a random-effect model in groups 2 (p = 0.000, *I*^*2*^ = 76.3%) ([Fig 4](#pone.0161150.g004){ref-type="fig"}). Considering the high heterogeneity of group 2, a stratified analysis was conducted in group2 through ethnicity and pathology disease, and *I*^*2*^ was still high in each subgroup ([Fig 5](#pone.0161150.g005){ref-type="fig"}), which made the subgroups' HRs difficult to pool.

![Forest plots of merged analyses of overall survival (OS) in association with sCLU expression in different groups.\
Forest plots of merged analyses of disease-free survival (DFS)/relapse-free survival (RFS). Squares and horizontal lines represent study-specific HRs and 95% CIs, respectively. The areas of the squares correspond to weights, and the diamonds represent overall HRs and 95% CIs. (A) Forest plots of merged analyses of overall survival (OS) in group 1. (B) Forest plots of merged analyses of overall survival (OS) in group 2. (C) Forest plots of merged analyses of overall survival (OS) in group3.](pone.0161150.g004){#pone.0161150.g004}

![Subgroup analyses of group 2.\
(A) shows the pathology-type subgroup analysis, and (B) shows the ethnicity subgroup analysis.](pone.0161150.g005){#pone.0161150.g005}

Publication bias {#sec012}
----------------

The funnel plots of the publication bias are presented in [Fig 6](#pone.0161150.g006){ref-type="fig"} respectively. They showed no obvious publication bias.

![Begg's funnel plots of the publication bias.\
Begg's funnel plots of the publication bias for overall merged analysis of OS or DFS/RFS. Each point represents a separate study. About the OS analysis, (A) and (B) represents group 1 and group 2 respectively. About the DFS/RFS analysis, (C) and (D) represents group 1 and group 3 respectively.](pone.0161150.g006){#pone.0161150.g006}

Discussion {#sec013}
==========

Tumour relapse and metastases always suggest a bad outcome for patients suffering from malignancy. Discovering an effective biomarker that can predict tumour progression is important so that an appropriate treatment can be applied. Patients with higher-risk biomarker expression can receive a more extensive treatment and be required of more frequent follow-up visits. The role of CLU in tumour prognosis is controversial and has been previously stated in many reviews. On one side, many studies have demonstrated that sCLU promoted tumourigenesis. For instance, sCLU has been found abnormally upregulated in various advance-stage and metastatic cancers and proven to be a biomarker for tumourigenesis and progression over the past decades\[[@pone.0161150.ref046]\]. The association of sCLU expression with tumour prognosis may be partially due to its biological function, especially in the field of antiapoptosis. sCLU protects tumour cells from apoptosis by stablising Ku70/Bax to prevent its actions on the mitochondrial membrane activating the phosphatidylinositol 3-kinase/protein kinase B pathway, modulating extracellular signal-regulated kinase 1/2 signaling and matrix metallopeptidase-9 expression, and increasing angiogenesis\[[@pone.0161150.ref004]\]. On the other side, though sCLU was found up-regulated in various advance-stage and metastatic cancers in many studies\[[@pone.0161150.ref046]\], data available on the Oncomine database showed that CLU transcripts were down-regulated in tumours as compared to normal tissues in many microarray analyses ([www.oncomine.org](http://www.oncomine.org)). According to existing clinical data, whether sCLU acts as a good or bad indicator in clinical tumour progression is still controversial.

Recently, many studies have facilitated advance in the research of CLU. First, several CLU mRNA isoforms have been identified, including Isoform 1, Isoform 2, and Isoform 11036\[[@pone.0161150.ref047]\]. Subsequently studies have been performed measuring the amount of different mRNAs coding for CLU, showing huge differences in mRNA isoform expression in different experimental systems\[[@pone.0161150.ref048], [@pone.0161150.ref049]\]. Second, specific mRNA CLU isoforms are also differentially regulated in cancer cells. At least two putative promoter regions have been discovered, respectively surrounding the transcription start site of Isoform 1 and Isoform 2\[[@pone.0161150.ref048]\]. In addition, CLU production process is dynamic and complicated and any factors related to sCLU production or excretion can influence sCLU expression\[[@pone.0161150.ref050]\]. Moreover, the regulation of NF-kB-activation is another proposed function of CLU. However, both NF-kB-stimulatory and -inhibitory properties have been described, which might be aroused from different CLU isoforms\[[@pone.0161150.ref051], [@pone.0161150.ref052]\]. All the aforementioned data showed that the mechanism of CLU in tumour is complicated and challenging.

Meta-analysis, as an effective tool, can provide more dependable results than a single research especially in explaining controversial conclusions. As a consequence, we took advantage of meta-analysis to analyse the possible association between sCLU and tumour prognosis. In the present work, actual clinical data showed contradictory results ([Table 1](#pone.0161150.t001){ref-type="table"}). This is the first meta-analysis to evaluate the relationship between sCLU IHC expression and the prognosis of patients with various cancers. Our RFS/DFS analyses revealed a pooled HR of 1.58 in group 1 and 1.79 in group 3, which suggested that sCLU acted as a bad outcome indicator in tumour relapse and metastases in both groups. OS analyses in the three different groups showed contradictory results (HR = 1.13, 1.14, and 1.64 in groups 1, 2, and 3, respectively). However, the result was not significant in all three groups. Insufficiently strong HRs and the accompanying insignificant CIs may imply that the role of sCLU in human malignancies is complex and controversial. sCLU can be a prognostic biomarker for relapse and metastasis, but its action on patient survival was weak based on our analysis.

We further analysed the heterogeneity of the three groups in the OS-related studies. Results showed that the heterogeneity of group 2 and group 3 were very strong (p = 0.000, *I*^*2*^ = 76.3%), in which the specimens were scored through sCLU staining intensity only. Secondary analyses were conducted to identify the origin of the heterogeneity. Subgroup analyses showed that the ethnicity and pathology subgroups did not obtain a smaller *I*^*2*^ ([Fig 5](#pone.0161150.g005){ref-type="fig"}). Meanwhile, sensitivity analysis results showed that no single heterogeneous study existed. This finding might suggest that the scoring method that only used staining intensity as an index can be inappropriate. By contrast contrary, scoring method both using staining proportion and intensity as a standard of the specimen can be more objective and accurate.

To distinguish the positive or negative expression of sCLU protein, these IHC studies in group 2 set a cutoff point according to expression intensity. The specific intensity of each tissue specimen was described as negative, weak, moderate, or strong according to a positive or negative control. Among them, negative- or weak-expression specimens were incorporated into the negative-expression group, and the others were incorporated into the positive group. Given that specific staining intensity was identified subjectively, the result changed from different pathologists and thus increased the heterogeneity of the studies in group 2.

By contrast, the studies in groups 1 and 3 used staining-cell proportion as a scoring method or as part of the scoring method, which was relatively objective. In group 3, the proportion of staining cells was recorded, and if \>10% cells were stained, the specimen was included in the positive group. In group 1, both intensity and proportion of staining cells were considered. Usually, intensity and proportion were scored separately in each specimen, and then the score values were added or multiplied. A median or mean value was then set as a cutoff point in these situations.

Finally, our conclusions should be considered with caution because of the following limitations. First, the IHC scoring methods and the cutoff points differed among various studies, and these factors caused by IHC substantially increased heterogeneity in our analyses. Although we divided our enrolled studies into three groups from the IHC methods, heterogeneity cannot be completely avoided because each study had little differences in scoring method. For instance, in group 1, some researchers used three as a cutoff point, whereas some chose the median score. Second, IHC intensity was judged by a pathologist, which inevitably made the IHC results subjective. Third, the number of enrolled participants was smaller in each group. Heterogeneity also arose from the pathological type and ethnicity.

Conclusions {#sec014}
===========

Our results suggested that sCLU was a potential biomarker for malignancy RFS/DFS. IHC methods can also become more standardised if both intensity and the proportion can be considered.
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